Evidence Hub

Tailored transethosomal systems for tadalafil transdermal delivery: Impact of Phosal and edge activators on skin permeation and cellular uptake

T. Asar, Hossam S. el-Sawy, A. M. Reda, Mohamed Ashraf, Amer H. Asseri, Abdelsattar M. Omar, Tarek A. Ahmed, K. El-Say

International Journal of Pharmaceutics: X, 2025

1 citation

Abstract

Tadalafil (TDLF), a Biopharmaceutics Classification System (BCS) Class II drug, exhibits poor aqueous solubility and extensive first-pass metabolism, which limits its therapeutic efficacy. We developed Phosal-based transethosomes (TrEthOs) to overcome these challenges, thereby enhancing transdermal delivery. A Box-Behnken design was employed to optimize the formulation by evaluating the effects of Phosal type, polyethylene glycol (PEG) 400 concentration, and cholesterol content. The optimized TrEthOs exhibited a mean vesicle size of 129.74 nm and an entrapment efficiency of 67.3%, ensuring efficient encapsulation of the drug. Ex vivo permeation studies demonstrated a cumulative TDLF permeation of 70.24% over 6 hours, with a steady-state flux of 19.49 × 10 -4 mg/cm 2 ·min. Confocal laser scanning microscopy confirmed deep skin penetration, while in vitro studies revealed significantly enhanced cellular uptake (P < 0.0001) and reduced cytotoxicity (IC₅₀ = 67.61 μg/mL) compared to pure TDLF (IC₅₀ = 34.85 μg/mL). The novel Phosal-based TrEthOs system presents a promising transdermal drug delivery strategy, potentially reducing dosing frequency and improving patient compliance. These outcomes emphasize the potential of advanced nanocarrier systems to optimize systemic bioavailability while minimizing adverse effects.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free